Form 4: Eli Lilly Director Defers Compensation into Stock

Eli Lilly Director Juan R. Luciano acquired 19.826 shares of common stock by deferring cash compensation, increasing his beneficial ownership to 16,455.857 shares.

Summary

• Juan R. Luciano, a Director of Eli Lilly & Co (LLY), acquired 19.826 shares of common stock.
• The transaction occurred on September 15, 2025, at a price of $748.19 per share.
• The shares were acquired by deferring cash compensation and converted into stock units under the Lilly Directors' Deferral Plan.
• These stock units will be settled in shares of common stock following Mr. Luciano's separation from service.
• Following this transaction, Mr. Luciano's direct beneficial ownership stands at 16,455.857 shares of common stock.
• The transaction was made pursuant to a Rule 10b5-1 plan.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. A director's decision to acquire shares, even through deferred compensation, generally signals confidence in the company's long-term prospects and aligns management interests with shareholders. This is a routine, positive governance action.

Positives

• The acquisition of shares by a director, even through deferred compensation, indicates alignment of management's long-term interests with those of shareholders.
• Participation in a Rule 10b5-1 plan demonstrates a pre-planned and systematic approach to insider transactions.

Future Outlook

The filing indicates that the acquired stock units will be settled in shares of common stock following the reporting person's separation from service, aligning future compensation with long-term company performance.

Management Comments

• Juan R. Luciano, a Director, elected to defer cash compensation into stock units under the Lilly Directors' Deferral Plan.

Industry Context

This transaction reflects a common practice in large publicly traded companies where directors elect to defer a portion of their cash compensation into company stock, often through a pre-established plan, to align their financial interests with long-term shareholder value.

Comparison to Industry Standards

• Deferring director compensation into company stock is a widely adopted corporate governance practice among S&P 500 companies, including pharmaceutical peers like Pfizer or Merck, as it fosters long-term alignment between directors and shareholders.
• The use of a Rule 10b5-1 plan for such transactions is standard practice to provide an affirmative defense against insider trading allegations, similar to plans used by executives at companies such as Johnson & Johnson or AbbVie.

Corporate Governance

Stakeholder Impact

• Shareholders: The transaction aligns the director's financial interests with long-term shareholder value, potentially fostering more shareholder-centric decision-making.
• Employees: No direct impact mentioned.

Next Steps

• The acquired stock units will be settled in shares of common stock following the reporting person's separation from service.

Key Dates

Keywords

Eli Lilly, LLY, Form 4, Insider Transaction, Director Compensation, Stock Acquisition, Rule 10b5-1